Leukemia Research
Volume 33, Issue 12 , Pages 1594-1598 , December 2009

Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes

  • Rong Wang

      Affiliations

    • Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, United States
    • ,
  • Cary P. Gross

      Affiliations

    • Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, United States
    • ,
  • Stephanie Halene

      Affiliations

    • Section of Hematology, Yale University School of Medicine, New Haven, CT, United States
    • ,
  • Xiaomei Ma

      Affiliations

    • Department of Epidemiology and Public Health, Yale University School of Medicine, New Haven, CT, United States
    • Corresponding Author InformationCorresponding author at: 60 College Street, Box 208034, New Haven, CT 06520-8034, United States. Tel.: +1 203 785 3880; fax: +1 203 785 6980.

Received 14 December 2008 ,Revised 30 January 2009 ,Accepted 3 February 2009.

References 

  1. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109:1536–1542
  2. Bennett J, editor. The myelodysplastic syndromes: pathobiology and clinical management. In: Cheson B, editor. Basic and clinical oncology, vol. 27. New York: Marcel Dekker; 2002.
  3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  4. Hoffman C, Rice D, Sung HY. Persons with chronic conditions. Their prevalence and costs. JAMA. 1996;276:1473–1479
  5. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582–1587
  6. Piccirillo JF, Feinstein AR. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer. 1996;77:834–842
  7. Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D. Comorbidity and survival disparities among black and white patients with breast cancer. JAMA. 2005;294:1765–1772
  8. Sanabria A, Carvalho AL, Vartanian JG, Magrin J, Ikeda MK, Kowalski LP. Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol. 2007;
  9. Jacot W, Colinet B, Bertrand D, et al. Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients. Ann Oncol. 2008;19:1458–1464
  10. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368:1894–1907
  11. Boehm A, Sperr WR, Leitner G, et al. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation. Eur J Clin Invest. 2008;38:945–952
  12. Pelz D, Nachtkamp K, Kündgen A, Strupp C, Haas R, Germing U. C015 Influence of comorbidity factors on the prognosis of patients with myelodysplastic syndromes (MDS). Leuk Res. 2007;31:S30–S31
  13. Della Porta MG, Kuendgen A, Malcovati L, et al. Myelodysplastic syndrome (MDS)-specific comorbidity index for predicting the impact of extra-hematological comorbidities on survival of patients with MDS. ASH Annu Meet Abstr. 2008;112:2677
  14. Della Porta MG, Malcovati L, Travaglino E, et al. A prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes. ASH Annu Meet Abstr. 2007;110:2453
  15. In:  Fritz A editors. International classification of diseases for oncology. 3rd ed.. World Health Organization; 2000;
  16. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189–199
  17. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835–3849
  18. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292–2302
  19. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV-3–IV-18
  20. Sharma G, Freeman J, Zhang D, Goodwin JS. Trends in end-of-life ICU use among older adults with advanced lung cancer. Chest. 2008;133:72–78
  21. Wong YN, Mitra N, Hudes G, et al. Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA. 2006;296:2683–2693
  22. Keating NL, Landrum MB, Meara E, Ganz PA, Guadagnoli E. Do increases in the market share of managed care influence quality of cancer care in the fee-for-service sector?. J Natl Cancer Inst. 2005;97:257–264
  23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–383
  24. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol. 1993;46:1075–1079discussion 1081–1090
  25. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002;40:IV-19–IV-25
  26. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162:2269–2276
  27. Anisimov VN. Carcinogenesis and aging 20 years after: escaping horizon. Mech Ageing Dev. 2008;
  28. Extermann M. Interaction between comorbidity and cancer. Cancer Control. 2007;14:13–22
  29. Read WL, Tierney RM, Page NC, et al. Differential prognostic impact of comorbidity. J Clin Oncol. 2004;22:3099–3103
  30. Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood. 2004;104:1550–1558
  31. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004;104:961–968
  32. Sorror ML, Maris MB, Sandmaier BM, et al. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005;23:3819–3829
  33. Mielcarek M, Burroughs L, Leisenring W, et al. Prognostic relevance of ‘early-onset’ graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. Br J Haematol. 2005;129:381–391
  34. Baron F, Maris MB, Sandmaier BM, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol. 2005;23:1993–2003
  35. Maris MB, Sandmaier BM, Storer BE, et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood. 2004;104:3535–3542
  36. Sorror ML, Sandmaier BM, Storer BE, et al. Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation. J Clin Oncol. 2007;25:4246–4254
  37. Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res. 2000;24:983–992
  38. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008;112:45–52

PII: S0145-2126(09)00064-2

doi: 10.1016/j.leukres.2009.02.005

Leukemia Research
Volume 33, Issue 12 , Pages 1594-1598 , December 2009

Article Tools

* Image Usage & Resolution